Michael Dykstra retweeted
Grateful to @MROQC1's efforts to deliver high quality radiation to michiganders!
Bone met RT in 5 or fewer fractions:
📈 Is increasing & quality measure launch is independently associated.
🏥 Is good for system resources
🚙 Is patient-centered
🏞️ Is environmentally friendly
This Post is from an account that no longer exists. Learn more
Michael Dykstra retweeted
From #RedJournal: @MROQC1 shows substantial variation in intended ADT use across a statewide consortium for men w/ intermed. risk prostate cancer and show a lack of consensus w/ the benefits and harms of ADT in this patient population. @mdsquared44 bit.ly/reddess1
Michael Dykstra retweeted
Wonderful farewell dinner for our graduating residents. Extremely bittersweet to see (most of) you fly the coop but you’ll always be part of the @UMichRadOnc family. It’s been such a joy to work with you all, but it’s time for you to show the world what you got! @MichRadOncRes
Michael Dykstra retweeted
Amazing experience to be part of the #YouthSummit at the Big House. So great to see the future leaders of healthcare! @UMichRadOnc @umichmedicine
Michael Dykstra retweeted
Seriously though, a PHYSICS ⚛ CURRICULUM is finally here!
@VarianMedSys & ARRO bring you this peer-reviewed resource, full of modules and ways to test yourself!
Register ⬇now for access just in time for @ABR_Radiology physics boards on June 25!
bit.ly/3wkV562
Michael Dykstra retweeted
ORATOR2 primary analysis from @drdavidpalma @ESTRO_RT #ESTRO24 (60 Gy + cis if 7th ed N2 vs essentially 3311 treatment) - RT with improved OS (and PFS)!
Michael Dykstra retweeted
What I learned in 🇨🇱 today … $5mill = one #radiotherapy machine☢️, can treat 10k patients. $5mill = 135 patients worth of trastuzumab. 🧐
@TheLancetOncol - tinyurl.com/6bry9a2a “an essential pillar in multi-D oncology…an inexpensive modality” - 👏🏽 well said @TargetingCancer
Michael Dykstra retweeted
This is what pains me about focal and the GU field and even organizations that standby silent:
We learn to maximize benefit and minimize harm through carefully conducted controlled trials. 99% of these tx are done off trial.
Most RCTs are negative bc we are wrong often even when ph2 promising. Focal phase 2 trials largely disappointing. Even ignoring that there is a >50% chance these tx harm more than help, but doctors are literally willing to take these pts cash and harm countless men. This is bc:
If focal was truly better they are harming millions of men by not answering the question carefully in a trial to change SOC and provide it to all…
And if focal is worse they are harming millions of men indefinitely by pretending it helps, bankrupting families, and causing irreversible harm.
There are places that have focal tumor boards and the institutions enable it. There is no good data to support using it, let alone pretend you have any clue who it is good for. It’s like having a focal brachy tumor board = anecdotes leading anecdotes. The decay of EBM.
Embarrassment for doctors to do off trial, disgrace the field stands by silent while these men are being harmed.
If focal is so amazing do the dang RCT to SBRT and mandate it be on trial. Otherwise just admit you happily take cash from patients for a treatment that may ultimately be worse for them than SOC and you have no good data to prove otherwise.
Many professions take ppls money. Sad this is rampant in GU. – at Shaker Heights, OH
100% agree @DrSpratticus
Here's a popular #HIFU company's web posting...
Vs data they reference vs other published data... (note their ref has no RP nor RT data). Yes failure def'n different for RP vs RT but drives salvage = more toxicity
Maybe they need to hire new webmaster?
Michael Dykstra retweeted
What an amazing day here at @MichRadOncRes welcome to our new residents! Can’t wait for 2025! 💙💛 #goblue
Michael Dykstra retweeted
Congrats to resident @SamReganMD on his talk at #HNCS24 on a phase 2 trial of FDG-PET based approach to selective de-escalation of chemoRT in early stage HPV+ oropharynx cancer! @UMichRadOnc
#HNCS24 Plenary: How can PET be used in de-escalation?
Compared to standard cohort, De-escalation based on mid-tx PET ➡️
🔘Similar LRC to standard cohort
🔘Similar PFS
🔘⬇️ Wt loss
🔘⬆️ QOL at 1 mo post Tx
Michael Dykstra retweeted
Please check out our new article in Lancet Oncology - The Radiation Planning Assistant: addressing the global gap in radiotherapy services @MDAndersonNews
thelancet.com/journals/lanon…
Michael Dykstra retweeted
A radiation oncologist at @UMichMedicine discussed a recent publication that explores how nucleotides can affect brain cancer's sensitivity or resistance to chemotherapy and radiation, potentially leading to breakthroughs in cancer treatment. myumi.ch/byk89
Michael Dykstra retweeted
Congrats to two of our residents, Michael Dykstra and Sam Regan, for winning Conquer Cancer Merit Awards for their ASCO GU symposium abstracts! Both will be presenting work done with @MROQC1.
conquer.org/news/conquer-can…
@mdsquared44 @SamReganMD @UMichRadOnc @UMichMedSchool
Michael Dykstra retweeted
🚨 EXTEND
Ph 2 pancreatic ca ≤ 5 metastases
1:1 R to MDT plus systemic therapy versus systemic therapy alone
mPFS 10.3 versus 2.5 months p=0.006
HR 0.43 (95% CI 0.20, 0.94; p=0.03)
Nice work! H/T @ebludmir
meetings.asco.org/2024-asco-…
Michael Dykstra retweeted
Hiya my friend @nytimes your scary and irresponsible headline inspired this OncoScan- but let's focus on the upside!!
We offer our @IJROBP @ASTRO_org scientific experts if you ever have questions about cancer treatments! As you can see, they are way smart.
redjournal.org/article/S0360…
Michael Dykstra retweeted
New research - Liu et al - Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial
thelancet.com/journals/langa…
#GITwitter #OncTwitter @OncoAlert
Michael Dykstra retweeted
🌟👏" "Empowering #women isn't just about changing lives; it's about shaping the future of our society. When women rise, we all thrive! 💪🌟
Sponsored by ACREOL @acreol_org , she recently attended and presented at the prestigious #AORTIC2023 conference,
Dr. Diane Ndoli, a Clinical Oncologist at Rwanda Military Hospital @RwaMilitaryHosp , made waves during the #AORTIC2023 with her groundbreaking work on supportive care for cancer patients as part of the @acreol_org project. 🌟
#ACREOL #AORTIC2023 #CancerResearch #SupportiveCare @NDOLIDNA @ntizimira @nazik_hammad @m_mutebi @KicukiroDistr @ASCO @CCan_org @DrZSB @OphiraG @jrgralow @helena_musau @ConquerCancerFd @akillesm @breastlessAfrik @zippyali @AORTIC_AFRICA @UwinkindiFranco @AkwiAsombangMD @ASCOPres @TheonesteManir8 @womeninGH #RwOT @JasonBakundukiz
Michael Dykstra retweeted
People often ask: Who is going to help clinicians understand basic concepts in AI, how to appraise clinical AI research, and how to incorporate it into clinical practice?
I point to efforts like this one led by @CAJamesMD and @AmerMedicalAssn. Nice work!
Unveiling the first module of our @AmerMedicalAssn foundational series on #AI at #AAMC23 👍 @CAJamesMD #ChangeMedEd
edhub.ama-assn.org/change-me…











































